Today, XtalPi announced that it has signed a Memorandum of Understanding (MOU) with the Experimental Drug Development Centre (EDDC), Singapore's national drug discovery and development platform hosted by A*STAR, for the expansion of their collaboration to encompass potential projects that will focus on the application of automated synthesis solutions and large language models in pharmaceutical research.

今天，XtalPi宣布已与a*STAR主办的新加坡国家药物发现与开发平台实验药物开发中心（EDDC）签署谅解备忘录（MOU），扩大合作范围，涵盖潜在项目，重点关注自动化合成解决方案和大型语言模型在制药研究中的应用。

Building upon an ongoing collaboration that was initiated in December 2022 to utilize artificial intelligence (AI) and automation to develop targeted therapies for non-small cell lung cancer, the new collaboration aims to expedite the conversion of scientific discoveries into robust pipeline assets by advancing the domain of intelligent automated pharmaceutical research.Under the MOU, the two parties will explore collaborations in the fields of automated chemical compound synthesis and AI-driven drug discovery, including the application of XtalPi's robotics and AI-driven drug design capabilities in EDDC's R&D, such as automated library synthesis and other drug chemical synthesis services.

在2022年12月启动的利用人工智能（AI）和自动化开发非小细胞肺癌靶向治疗的持续合作的基础上，新合作旨在通过推进将科学发现转化为强大的管道资产智能自动化药物研究领域。根据MOU，双方将探索自动化化合物合成和AI驱动药物发现领域的合作，包括XtalPi机器人技术和AI驱动药物设计能力在EDDC研发中的应用，如自动化图书馆合成和其他药物化学合成服务。

XtalPi's array of automated workstations can provide significant remote support to EDDC's R&D efforts, generating large-scale, high-quality data that can enhance EDDC's current drug development processes. By developing cutting-edge computational tools and industry practices, the partners aim to leverage robotics and AI in therapeutic discovery.XtalPi and EDDC will also look into jointly exploring the potential of advanced AI models, including large language models (LLM), to drive biopharmaceutical innovation.

XtalPi的一系列自动化工作站可为EDDC的研发工作提供重要的远程支持，生成大规模，高质量的数据，从而增强EDDC当前的药物开发流程。通过开发尖端的计算工具和行业实践，合作伙伴旨在利用机器人和AI进行治疗发现。XtalPi和EDDC还将研究共同探索先进AI模型（包括大型语言模型（LLM））的潜力，以推动生物制药创新。

The partners aim to extract valuable insights and develop robust methodologies in areas such as target discovery and molecular design by integrating high-throughput automated exper.

合作伙伴旨在通过整合高通量自动化专家，提取有价值的见解并在目标发现和分子设计等领域开发强大的方法。